Amolin
PreclinicalSmall molecule
Amolin is one of 34 small molecule programs targeting First-line. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Helicobacter Pylori Eradication
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Flagyl
DDePuy Orthopaedics
Approved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Potassium Citrate
MMission Pharmacal
Approved
Levaquin
WWim Janssens
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aciphex
Akero TherapeuticsApproved
Minocin
TTriax
Approved
Furoxone
UUniversity of New Hampshire
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
First-line1 trial
Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment
Completed·—·N/A·NCT05152004·240 enrolled
Helicobacter Pylori Eradication1 trial
Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Completed·—·N/A·NCT02596620·164 enrolled
Helicobacter Pylori1 trial
Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy
Completed·—·N/A·NCT03383003·240 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amolin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CChang Gung Memorial Hospital